REVA Medical (ASX:RVA) is a medical device company focused on the development of bioresorbable polymers for vascular applications. Our mission is to restore patient health for life through the application of biomaterials in the development and sale of implantable medical devices.
REVA is a pioneer of novel bioresorbable polycarbonate polymers derived from the naturally occurring tyrosine amino acid. In its 20-year history, the company has developed four polymer families. The company’s first product, called Fantom, is a drug-eluting bioresorbable scaffold for the treatment of coronary artery disease. It is made with Tyrocore, REVA’s proprietary polycarbonate-based polymer designed specifically for vascular scaffolds.
Cardiovascular disease is the leading cause of death worldwide. Coronary artery disease is a heart condition where the buildup of plaque in the coronary arteries restricts the flow of blood to the heart muscles. Fantom was developed as an alternative to metallic stents to restore blood flow to blocked coronary arteries. Unlike metallic stents, which are a permanent implant, bioresorbable scaffolds are designed to disappear (or “resorb”) from the body over time. This resorption is intended to allow the return of natural movement and function to the artery.